Berenberg analyst Kerry Holford lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,050 and keeps a Buy rating on the shares.

We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are ...

Alcott is known for his starring roles in the Showtime Original series Dexter: New Blood and The Good Lord Bird, with ...

Zepbound, as expected, was more effective in promoting weight loss. Eli Lilly's Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...

Enter Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the makers behind blockbuster glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro, Zepbound, Ozempic, and Wegovy -- all of which are ...

VectSharp is a library to create vector graphics (including text) in C#, without too many dependencies. VectSharp is written using .NET Core, and is available for Mac, Windows and Linux. Since version ...

The Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020.

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop selling ...